Senti Biosciences Holdings
SNTI
23 hedge funds and large institutions have $27.8M invested in Senti Biosciences Holdings in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
5% more funds holding
Funds holding: 22 → 23 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.16% less ownership
Funds ownership: 3.24% → 3.08% (-0.16%)
37% less capital invested
Capital invested by funds: $44.4M → $27.8M (-$16.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$839K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$274K |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$232K |
| 4 |
TM
Triatomic Management
Palo Alto,
California
|
+$111K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
-$1.49M |
| 2 |
Morgan Stanley
New York
|
-$1.18M |
| 3 |
FMN
Financial Management Network
Mission Viejo,
California
|
-$396K |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$226K |
| 5 |
VF
Virtu Financial
New York
|
-$43K |
SNTI Hedge Fund Activity: Q3 2022 in Review
23 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Senti Biosciences Holdings (SNTI) for Q3 2022, worth a combined $27.8M — down 37% from $44.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SNTI positions and 5 closed out — a net gain of 1 holder — while 8 added to existing stakes and 2 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $839K. The largest seller was CAAS Capital Management, exiting entirely with an estimated $1.49M sold.
- 23 institutional investors held Senti Biosciences Holdings (SNTI) as of Q3 2022, up from 22 in Q2 2022.
- Funds reported $27.8M of Senti Biosciences Holdings stock for Q3 2022, down 37% quarter-over-quarter.
- 6 funds opened new Senti Biosciences Holdings positions in Q3 2022 and 5 closed out, a net change of +1 holder.
- The largest Senti Biosciences Holdings buyer in Q3 2022 was T. Rowe Price Associates, an estimated $839K added.
- The largest Senti Biosciences Holdings seller in Q3 2022 was CAAS Capital Management, an estimated $1.49M sold.
Based on aggregated 13F filings for Q3 2022.